These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19075480)

  • 1. Long-term coronary endothelial function after zotarolimus-eluting stent implantation. A 9 month comparison between zotarolimus-eluting and sirolimus-eluting stents.
    Shin DI; Seung KB; Kim PJ; Chang K; Choi JK; Jeon DS; Kim MJ; Lee MY; Chung WS
    Int Heart J; 2008 Nov; 49(6):639-52. PubMed ID: 19075480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction.
    Kim JW; Seo HS; Park JH; Na JO; Choi CU; Lim HE; Kim EJ; Rha SW; Park CG; Oh DJ
    J Am Coll Cardiol; 2009 May; 53(18):1653-9. PubMed ID: 19406340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction.
    Shin DI; Kim PJ; Seung KB; Kim DB; Kim MJ; Chang K; Lim SM; Jeon DS; Chung WS; Baek SH; Lee MY
    Int Heart J; 2007 Sep; 48(5):553-67. PubMed ID: 17998765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses.
    Hamilos M; Sarma J; Ostojic M; Cuisset T; Sarno G; Melikian N; Ntalianis A; Muller O; Barbato E; Beleslin B; Sagic D; De Bruyne B; Bartunek J; Wijns W
    Circ Cardiovasc Interv; 2008 Dec; 1(3):193-200. PubMed ID: 20031678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study.
    Rusinaru D; Vrolix M; Verheye S; Chowdhary S; Schoors D; Di Mario C; Desmet W; Donohoe DJ; Ormiston JA; Knape C; Bezerra H; Lansky A; Wijns W;
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1141-50. PubMed ID: 25044635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting stent.
    Kim JW; Suh SY; Choi CU; Na JO; Kim EJ; Rha SW; Park CG; Seo HS; Oh DJ
    JACC Cardiovasc Interv; 2008 Feb; 1(1):65-71. PubMed ID: 19393147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological, Functional, and Biological Vascular Healing Response 6 Months After Drug-Eluting Stent Implantation: A Randomized Comparison of Three Drug-Eluting Stents.
    Nakata T; Fujii K; Fukunaga M; Shibuya M; Kawai K; Kawasaki D; Naito Y; Ohyanagi M; Masuyama T
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):350-7. PubMed ID: 26526816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.
    Hamilos MI; Ostojic M; Beleslin B; Sagic D; Mangovski L; Stojkovic S; Nedeljkovic M; Orlic D; Milosavljevic B; Topic D; Karanovic N; Wijns W;
    J Am Coll Cardiol; 2008 Jun; 51(22):2123-9. PubMed ID: 18510958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of zotarolimus-eluting stents with sirolimus-eluting and paclitaxel-eluting stents: intimal hyperplasia and vascular changes assessed by volumetric intravascular ultrasound analysis.
    Kang SJ; Mintz GS; Park DW; Lee SW; Kim YH; Lee CW; Han KH; Kim JJ; Park SW; Park SJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):139-45. PubMed ID: 21364151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
    Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 3-year clinical outcomes between Resolute™ zotarolimus- and sirolimus-eluting stents for long coronary artery stenosis.
    Im E; Kim BK; Ko YG; Her AY; Choi HH; Shin DH; Kim JS; Choi D; Jang Y; Hong MK
    J Interv Cardiol; 2013 Aug; 26(4):378-83. PubMed ID: 23844852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
    Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
    Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of sirolimus-eluting stent versus bare metal stent evaluation of the coronary endothelial dysfunction in the same patient presenting with multiple coronary artery lesions: the CREDENTIAL study.
    Mischie AN; Nazzaro MS; Fiorilli R; De Felice F; Musto C; Confessore P; Parma A; Boschetti C; Violini R
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E184-91. PubMed ID: 23359371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
    Sethi A; Bahekar A; Bhuriya R; Bajaj A; Singh PP; Arora R; Khosla S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):544-56. PubMed ID: 23177483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents.
    Nakazawa G; Finn AV; John MC; Kolodgie FD; Virmani R
    Am J Cardiol; 2007 Oct; 100(8B):36M-44M. PubMed ID: 17950831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation.
    Fuke S; Maekawa K; Kawamoto K; Saito H; Sato T; Hioka T; Ohe T
    Circ J; 2007 Feb; 71(2):220-5. PubMed ID: 17251671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.
    Togni M; Windecker S; Cocchia R; Wenaweser P; Cook S; Billinger M; Meier B; Hess OM
    J Am Coll Cardiol; 2005 Jul; 46(2):231-6. PubMed ID: 16022947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.